No downgrade anywhere..just the fear mongers coming out of skeleton closets..I see hugh bids piling up..I just got 2k more at these prices..unbelievable. Wait until Nov 5th..another confident CC and the pps will be back to high 5's before the results are out.

The fact Celsion management did NOT take advantage of these prices to do any offering speaks volume..MT must be very confident on the results...

No downgrade anywhere..just the fear mongers coming out of skeleton closets..I see hugh bids piling up..I just got 2k more at these prices..unbelievable. Wait until Nov 5th..another confident CC and the pps will be back to high 5's before the results are out.

The fact Celsion management did NOT take advantage of these prices to do any offering speaks volume..MT must be very confident on the results...

So what's your point ? This article is old. TIA

I was just kidding. I owe bioman for all the profits I am sitting on CLSN and ctix. I intend to add Imuc more if it dips further.

Agree, move over bioman (lol

Just remember IC 107 was featured none other than by Dr Sanjay Gupta on CNN recently and many of the treated patients are still alive

Bullshit looks like u sold earlier and want to get back in cheaper ? Where is all your 'bull' theory and IMUC being part of Mag7 ? Lol.....

While we all did not like Singh leaving, wish you had pounded the table bit harder on your take on Yu. I still believe the science has high promise.

I doubt Yu would have done anything on his own, he being interim CEO. It got to be the board's decision. I expect some PR on what the company plans to do going forward. Also if Singh wants totally out, he would have sold his shares. Usually the insiders who have such a huge holdings dispose their share thru pipe and such plans are made public thru 8-k filings etc.

Thanks for clarifying.. I added more yesterday. I think the vote next month will be positive.

FWIW, just scanned the 3Q filings of the top few Institutional holders and none of them have sold out...good sign...

I plan to add if the price dips to 2 tomorrow..PII results are not too far off..

To quote another poster 'aria2010' from biotech values board,

Apparently, they did a warrant deal with Symphony years ago for the rights to Hepsilev. Today Symphony allegedly sold 6 million shares that Blackrock purchased @ $4.86.

Sounds plausible b/c avg 30 day vol is 1.5 mil and today traded 6 mil. Huge buys and sells all day. Must have spooked the market or set off the short sellers and closed at $4.70.

A good entry right now IMO

Oxford asset management buys 633k shares end of 3Q !

http://www.sec.gov/Archives/edgar/data/1438284/000108514612001231/0001085146-12-001231-index.htm

For those who are new to DVAX, here is the link that shows PIII outcome on DVAX vaccine HEPLISAV

http://investors.dynavax.com/releasedetail.cfm?releaseid=592848

No red flags that I see that Advisory Committe when they meet on 14th next month will take notice to.

Great find ! Thank you. I was wondering myself on how come the tentative schedule was not confirmed yet.

DVAX should go back to 5 early next week.

I think the drop is due to advisory committee meeting being cancelled for Nov 14/15 (at least it's no longer on the FDA's calendar). It's mildly positive for DVAX insofar as FDA does not think any serious issues or overview need to be made before the PDUFA review.

It could be that FED Advisory Committee meeting for DVAX that was tentatively scheduled for Nov 14/15th is no longer on the FED's confirmed calendar.

Tentative

http://www.fda.gov/AdvisoryCommittees/Calendar/ucm153468.htm

Confirmed

http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm

Also your short % gives a wrong picture... sells do not mean they are 'shorts'. Based on daily NASDAQ trades (Buys an Sells), it looks like this is in accumulation mode probably with great anticipation into mid-November ADCOM meeting. I expect positive review which will take DAVX to $8+ easily.

I don't understand. 50.50% shorted ? How do you know ? They all could very well be short term sellers / traders who want to make few quick bucks.

Agree. Does anyone know or can we find out which of funds added or sold out their position in CLSN end of 3Q ?

A must read regarding CLSN coverage in FUS Conference this week at Washington DC.

http://celsion.blogspot.com/

FUS Foundation Conference

There are multiple references to Celsion TDOX approach and will be referred in front of numerous delegates next week. The conference is October 14 thru 17. Good additional press for CLSN



http://fusfoundation.org/media/FUSF_Symposium_2012_Program_WebVersion.pdf

Yes

ok. Thanks for the heads up..if it dips I will add more but unlikely, IMHO..

Yeah ? The PPS is rock steady at ~ 4.80 for some time. You have right to your wishes...lol..but don't we all ?..to get some cheapo shares

Well said Again I say to all newbies...slide 16 in Dr. Poon's recent presentation that's available on Celsion's website tells all..HEAT WILL succeed..mark this post.

rand0m, Hepseliv will get approved as the results speak for themselves. Cramer has given a boost as well. FYI, this stock has been picked by $heff's $tation of $tocks & $olid DD board who usually hold their buys until the PDUFA date.

FWIW, I bought a boat load during last few days

Yep..looks like a typo..

Re-posting Yahoo msg by the one & only one ODAAT

fusfoundation org / media / FUSF_Symposium_2012_Program_WebVersion . pdf

Page 85
Page 104

and our good friend Dr. Brad Wood from the NIH will Shirley be mentioning Celsion in the main presentation on emerging technologies.

- Odaat

Bought more CLSN today as the anemic volume says it all. This is the calm before the storm. Data would be locked in anytime now (definitely by Nov 1st). Even a 50% improvement will be an outstanding outcome..

Let me be very clear..I am not selling a single share until FDA approval comes along. I agree with bioman that the news is not only old but irrelevant in big scheme of things that CLSN is going to bring to the shareholders...ORBIMED is a reputed fund and they would not have bought boat load of shares without DD that includes 'who is who' on the Celsion's team..

Lol..no intention to tie any of this 'crap' from the past to recent put events..just sounded odd to find such an history (assuming it's the same guy). The point to note is Raj Prabhakar is not in the board; so I doubt he is privy to any of the board 'talks'. MT is not stupid..

Though the info related to his past experience is limtied on the Celsion website, here is Linkedin URL that confirms his past work at Wasserstein Perella and I should add the time period of two years (1995 to 1997) agrees when the insider trading occurred.

http://www.linkedin.com/pub/raj-prabhakar/0/398/a2

I really hope it's the other 'John'..lol..two facts seem to be same however, graduating from MIT and worked as analyst at Wasserstein, Parella. What are the odds

All,

Up front I will apologize if my note below stris up some controversy but cannot help posting here hoping some clarification would be offered.

While looking (just plain curious) into Raj Prabhakar's background (he is Executive Director, Strategic Planning & Business Development @ Celsion) and unless he is different Raj, I was bit surprised that he was indited in insider trading fraud around 1995 when he was an analyst at Wasserstein, Parella.

If indeed he is the same Raj, how the heck, Celsion offered him the Management job ?

http://www.prnewswire.com/news-releases/former-investment-banking-firm-employee-pleads-guilty-to-securities-fraud-reports-us-attorney-74348912.html

I saw the same snafu..but liked the general take of the analyst as path-breaking science..

http://seekingalpha.com/article/919561-casey-analyst-forecasts-explosive-biotech-growth?source=yahoo

Just thinking loud...as a rough model, if you consider the stratification of patients between 3-5 cm & 5-7 cms lesions, the RFA efficacy is significantly poor on the later range (5-7) (refer to Celsion's presentation deck by Dr. Poon in september).

Ad with majority of patients (say ~65%) are in 3-5 range with remaining 35% on the >5 range, we have already a high odds of TDOX beating RFA up to 35% of the patients population. Another 15 to 20% from 3-5 range will easily total up to 50% or morein favor of TDOX as a whole. We just need to show a minimum of 33% to get TDOX approved.

Never thought that way but very plausible...

Bioman, while the author of that post is 'clinically' correct, he is net neutral. So if I have large position I will be nervous as hell. However Knowing what we know about celsion's science, the odds are high for the results to be positive.

Which Calls ? TIA